offmann & Partner is pleased to announce that it has advised the shareholders of Nostos Genomics GmbH (“Nostos”) as M&A advisors in the successful acquisition by Limbus Medical Technologies GmbH (“Limbus”). Two leaders in genomic software are coming together – combining Limbus’ clinical-grade workflows with Nostos’ cutting-edge AI technology for variant interpretation.